Jeff Hansen
| This email address is being protected from spambots. You need JavaScript enabled to view it.Research Editor
jeffhans@uab.edu | (205) 209-2355Communicates UAB research discoveries and initiatives from across the university for a variety of audiences.
Specific beats:
- Alabama Drug Discovery Alliance
- Biochemistry and Molecular Genetics
- Biomatrix Engineering and Regenerative Medicine
- Cell biology
- Center for Biophysical Sciences and Engineering
- CCTS
- Center for Metabolic Bone Disease
- Microbiology
- Neurobiology
- Comprehensive Neuroscience Center
- Pathology, research shared with MS2
- Pharmacology and Toxicology
- Physiology and Biophysics
- UAB Research Foundation/IIE
- Research Administration
Examination of a larger group of patients extends the clinical manifestations first described 11 years ago.
This research suggests a therapeutic approach to treating human heart failure.
This novel mechanism links epigenetic changes to translational control.
Sensitive, specific assays are needed to ensure the safety of inter-species transplants for patients needing new organs like kidneys and hearts.
The goal is an early warning system to block incipient seizures for patients where medications have failed.
This remarkable ability has clinical implications for humans.
The symposium puts a spotlight on interdisciplinary research at the University of Alabama at Birmingham.
This discovery may lead to personalized care for congestive heart failure, also known as ischemic cardiomyopathy.
These newborn neurons in the dentate gyrus become less excitable after three weeks, a crucial step for mature functioning.
The drug targets enzymes that control the immune response and spleen macrophages.